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Abstract
Background: The luminal subtype of breast cancer is sensitive to anti-estrogen therapy and shows a better
prognosis than that of human epidermal growth factor receptor2 (HER2)-enriched or triple-negative breast
cancer. However, the luminal type of breast cancer is heterogeneous and can have aggressive clinical
features. We investigated the clinical implications of single hormone receptor negativity in a luminal B HER2-
negative group.
Methods: We collected luminal B HER2-negative breast cancer data that were estrogen receptor (ER) and/or
progesterone receptor (PR) positive, Ki 67 high (>14 %), and HER2 negative and divided them into the ER-
and PR-positive group and the ER- or PR-negative group. We analyzed the clinical and pathological data and
survival according to ER or PR loss.
Results: There were no statistical differences in TNM stage, breast and axillary operative methods, or
number of tumors between the ER- and PR-positive group and ER- or PR-negative group. However, the
ER- or PR-negative group was associated with older age (≥45 years), higher histological grade, lower Bcl-2
expression, and far higher Ki 67 (>50 %). Disease-free survival (DFS) and overall survival (OS) were shorter
in the ER- or PR-negative group than that in the ER- and PR-positive group (p = 0.0038, p = 0.0071).
Conclusions: ER- or PR-negative subgroup showed worse prognosis than ER- and PR-positive subgroup in
the luminal B HER2-negative group. We could consider the negativity of ER or PR as prognostic marker in
luminal B HER2-negative subtype of breast cancer.
Keywords: Breast cancer, Estrogen receptor, Luminal B, Progesterone receptor, Prognosis
Background
Gene expression profiling studies for breast cancer
have unveiled that breast cancer has very heteroge-
neous biological characteristics and at least four mo-
lecular distinct subtypes, such as luminal A and B,
human epidermal growth factor receptor2 (HER2)-
enriched, and basal-like subtypes have been identified
over the few last decades [1–3]. Personalized therapy
according to gene expression profiles for breast can-
cer patient has been possible to achieve optimal
therapeutic effects [4–6]. Many investigators have
been making a more progresses for specific clinical
conditions in breast cancer patients, such as
inflammatory breast cancer, recurrent or metastatic
breast cancer, hereditary breast cancer, and basal-like
breast cancer [7–11].
The estrogen receptor (ER) and progesterone recep-
tor (PR) are traditional prognostic and predictive fac-
tors in breast cancer, and both of them are the
mainstays of gene expression profiles to determine
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intrinsic breast cancer subtypes. ER- or PR-positive
breast cancers are classified as the luminal subtype,
which have a more favorable prognosis and are more
responsive to anti-estrogen therapy than that of ER-
and PR-negative breast cancer [12–14]. However, the
luminal subtype of breast cancer is very heteroge-
neous and occasionally has very aggressive clinical
features. Luminal type breast cancer has two biologic-
ally distinct subtypes, luminal A and luminal B, and it
is well known that luminal B subtype have higher
proliferative characteristics and poorer prognosis than
those of luminal A [15].
A number of studies have been reported that luminal
B subtype is dramatically distinct from luminal A sub-
type at the cellular signaling pathway and DNA levels,
including growth factor receptors, such as epidermal
growth factor receptor (EGFR; HER1) and HER2 as well
as its downstream signaling pathway [16]. The St. Gal-
len International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2013 distinguished lu-
minal A-like breast cancer from luminal B-like disease
based on immunohistochemical stains of ER, PR, and
Ki-67 status without a requirement for molecular diag-
nostics. Recently, we have figured out the heterogeneity
of luminal B HER2-negative group from our consecu-
tive clinical studies, and we wanted to find out which
factors affect the disease prognosis that probably re-
lated with disease heterogeneity within luminal B sub-
type. We performed this study to determine the clinical
implications of single hormone receptor loss by immu-
nohistochemical (IHC) staining methods in a luminal B
HER2-negative group.
Methods
We collected clinical and pathological data from pa-
tients with breast cancer who underwent breast sur-
gery and treatment between January 2004 and
December 2014 at Sanggye Paik Hospital. Among the
769 patients, we selected 183 with luminal B HER2-
negative breast cancers that were ER or PR positive,
Ki-67 > 14 %, and HER2 negative. We divided them
into two groups of the ER and PR positive group and
the ER or PR negative group. ER and PR positive
group defined as both hormonal receptor showed
positive reaction. These two group was compared
disease free survival (DFS) and overall survival (OS)
between the two groups. We also analyzed the
clinical and pathological data of each group, includ-
ing age, breast and axilla operative methods, tumor
type, TNM stage, histological grade, nuclear grade,
number of tumors, Ki-67 and Bcl-2 expression, and
recurred or metastatic sites. We choose median 45
age, for statistical convenience.
IHC staining for ER, PR, Bcl-2, and Ki 67
The ER NCL-1-ER-6F11 and PR NCL-L-PGR-312
liquid mouse monoclonal antibodies (Leica Microsys-
tems Inc., Newcastle Upon Tyne, UK) diluted 1:80
with normal goat serum (diluted 1:5 TBS) were used
as the primary antibodies for the ER and PR assays,
respectively. The secondary antibody was goat anti-
mouse peroxidase conjugated immunoglobulin, and
3,3′-diaminobenzidine tetrahydrochloride (DAB) was
used as the chromogen. We scored ER and PR as 0,
1+, 2+, and 3+ according to staining intensity with a
description of the percentage related to the propor-
tion of stained nuclei in 10 high power fields [17].
We defined ER and PR positivity as any positive score
or a percentage greater than zero. We converted the
intensity scores and proportion percentages into the
Allred score [18]. We determined Allred score 0, 2 is
negative, and 3 to 8 is positive [19].
We performed IHC for Bcl-2 and Ki-67 using the
avidin-biotin peroxidase complex method with ami-
noethylcarbazole as the chromogen and the Vectastain
ABC Elite kit (Vector Laboratories, Burlingame, CA,
USA). We counterstained the sections with Mayer’s
hematoxylin. Sections was incubated in monoclonal
mouse anti-human Bcl-2 oncoprotein to assess Bcl-2
(1:100; Dako, Glostrup, Denmark), and brown nuclear im-
munostaining was examined. Sections were incubated
with monoclonal mouse anti-human Ki-67 antigen for the
Ki 67 measurements (1:100; Dako), and brown nuclear
immunostaining was examined [17]. We defined Bcl-2
overexpression as Bcl-2 intensity over 10 %. In addition,
low PR expression was defined as Allred score 3, 4. In Ki-
67, we choose cutoff value at 50 %. According to modified
2013 St. Gallen Consensus, high Ki-67 defined 20 % cut-
off. Nevertheless, we wanted to know higher Ki67 labeling
index might have association with ER or PR expression.
IHC staining for HER2/neu
We performed IHC of the HER2/neu protein on 4-μm-
thick paraffin embedded tissue sections on poly-L-lysine-
coated slides. After deparaffinization and blocking of
endogenous peroxidase, we performed HER2/neu immu-
nostaining using the rabbit anti-human c-erbB-2 onco-
protein as the primary antibody (Dako) at a 1:100
dilution. Binding of the primary antibody was detected
using the Dako Quick-Staining, labeled streptavidin-
biotin system (Dako, Carpentaria, CA, USA), followed
by adding the DAB chromogen. Two pathologists scored
each slide according to the manufacturer’s recom-
mended criteria in a blinded fashion. We red immuno-
staining in a semi-quantitative manner and graded as
follows: 0, 1+, 2+, and 3+. We designated intensity
scores of 0 or 1+ as negative expression and 3+ as posi-
tive expression for HER2/neu. We considered a 2+ score
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as equivocal, which was subjected to silver-enhanced in
situ hybridization (SISH) analysis [17].
SISH for HER2
We performed HER2 SISH on the Ventana Benchmark
automated instrument (Ventana Medical Systems,
Tucson, AZ, USA), according to the manufacturer’s proto-
cols for INFORM HER2 DNA and chromosome 17
probes. We performed testing for the HER2 gene and
chromosome 17 on sequential sections. Two sections were
baked at 60 °C for 20 min. The HER2 DNA probe was de-
natured at 95 °C for 12 min, and hybridization was per-
formed at 52 °C for 2 h. The chromosome 17 probe was
denatured at 95 °C for 12 min, and hybridization was per-
formed at 44 °C for 2 h. After hybridization, appropriate
stringency washes were performed three times at 72 °C for
the HER2 probe and three times at 59 °C for the chromo-
some 17 probe. Both DNP-labeled probes were visualized
using a rabbit anti-DNP primary antibody and the ultra-
View SISH Detection Kit (Ventana). The slides were
counterstained with hematoxylin for examination by light
microscopy. Evaluation of HER2 gene amplification status
was performed in a blinded manner using the ASCO/CAP
guidelines [20].
Statistical methods
We used the chi-square test to analyze the clinic-
pathologic factors affecting prognosis between the ER-
or PR-negative group and the ER- and PR-positive
group. We analyzed the difference in DFS between the
ER- or PR-negative and the ER- and PR-positive groups
by the Kaplan–Meier method. A univariate analysis of
the clinic-pathologic factors affecting prognosis in both
groups was conducted with the log-rank test. We used
the Cox multivariate regression model for the multivariate
analysis. MedCalc Statistical Software ver. 15.5 software
(MedCalc Software, Ostend, Belgium; https://www.med-
calc.org; 2015) was used for the statistical analysis. We
considered a p value <0.05 as statistically significant value.
Results
We collected 184 luminal B HER2-negative breast
cancers from 769 patients with breast cancer. Among
them, ER negative observed in four patients and PR
negative in 20 patients. Thus, the ER- and PR-positive
group included 160 cases and the ER- or PR-negative
group had 24. PR-negative group included 20 cases, PR
low group had 44, and PR high group had 120.
Univariate and multivariate analyses of the pathologic
characteristics according to ER or PR status
The median age of the patients was 48.5 years in the
ER- and PR-positive group and 55.5 years in the ER-
or PR-negative group. A significant difference between
the ER- and PR-positive and ER- or PR-negative
groups was detected when we used 45 years as the
age cutoff value (p = 0.0336). Fifty-five patients
(29.9 %) were TNM stage I, 92 (50.0 %) were stage II,
33 (17.9 %) were stage III, and 4 (2.2 %) were stage
IV. In total, 129 patients (70.1 %) received breast-
conserving surgery and 55 received mastectomy.
Axillary lymph node dissection was performed in 112
patients (60.9 %), sentinel lymph node biopsy in 70
patients (38.0 %), and an axillary procedure was omit-
ted in 2 patients. No significant differences in TNM
stage, operative method, axillary lymph node evalu-
ation method, or number of tumors were observed
between the ER- and PR-positive and ER- or PR-nega-
tive groups (Table 1).
However, the ER- or PR-negative group was signifi-
cantly correlated with a lower Bcl-2 (≤10 %) expression
(p = 0.0006) and a far higher Ki-67 index (>50 %) (p =
0.0167) than those in the ER- and PR-positive group
(Table 1). In terms of relapse, bone and liver metastases
were significantly more frequent in the ER- or PR-
negative group than those in the ER- and PR-positive
group (p = 0.0297, p = 0.0093, respectively) (Table 2).
The multivariate analysis revealed that Bcl-2 expression
(p = 0.0012) was significantly related with ER or PR
negative, respectively (Table 3).
Adjuvant therapies in luminal B HER2-negative breast
cancer
Adjuvant systemic chemotherapy was performed for 133
of the 160 patients in the ER- and PR-positive group
(83.1 %) and for 22 of the 24 patients in the ER- or PR-
negative group (91.7 %) The chemotherapy regimens were
anthracycline and/or taxane-based, cyclophosphamide/
methotrexate/5-fluorouracil, and cyclophosphamide/vino-
relbine/5-fluorouracil.
Adjuvant hormonal therapy was performed for 148 of
the 160 patients in the ER- and PR-positive group
(92.5 %) and for 22 of the 24 patients in the ER- or PR-
negative group (91.7 %). A slight difference in the choice
of drugs was observed between the two groups. The se-
lective estrogen receptor modulators (SERM), such as
tamoxifen and toremifene, were prescribed more
frequently in the ER and PR positive than that in the
ER- or PR-negative group (62.5 vs. 37.5 %). In addition,
aromatase inhibitors, such as anastrozole and letrozole,
were prescribed more frequently in the ER- or PR-
negative group than those in the ER- and PR-positive
group. (54.2 vs. 30.6 %) (p = 0.0579).
In total, 110 (68.7 %) of the 160 patients in the ER-
and PR-positive group, and 17 (70.8 %) of the 24 in the
ER- or PR-negative group received radiation therapy for
breast and/or regional axillary lymph nodes (Table 1).
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DFS and OS based on ER or PR status
To find out the impact of ER or PR negativity to sur-
vival of the luminal B HER2-negative breast cancer,
we analyzed DFS and OS according to the ER or PR
status. We could see the facts that DFS and OS were




N = 160 (%)
ER or PR
negative
N = 24 (%)
p value
Age (years) median 48.5 55.5 0.0336
= or <45 59 (36.9) 3 (12.5)
>45 101 (62.1) 21 (87.5)
TNM stage (AJCC 8th) 0.1061
I 50 (31.2) 5 (20.8)
II 81 (50.6) 11 (45.8)
III 27 (16.9) 6 (25.0)
IV 2 (1.3) 2 (8.3)
Breast operation 0.8761
BCS 113 (70.6) 16 (66.7)
Mastectomy 47 (29.4) 8 (33.3)
Axillary node operation 0.2088
SLNB 63 (39.4) 7 (29.2)
ALND 96 (60.0) 16 (66.7)
omit 1 (0.6) 1 (4.2)
Histologic type 0.1587
Invasive ductal carcinoma 142 (88.8) 22 (91.7)
Invasive Lobular carcinoma 5 (3.1) 2 (8.3)
Mucinous carcinoma 6 (3.8) 0 (0)
Papillary carcinoma 6 (3.8) 0 (0)
Micropapillary carcinoma 3 (1.9) 0 (0)
Apocrine carcinoma 1 (0.3) 0 (0)
Histologic grade 0.4421
II 31 (19.4) 8 (33.3)
III 101 (63.1) 16 (66.7)
Not available 28 (17.5) 0 (0)
Nuclear grade 0.9403
I 82 (51.2) 14 (58.3)
II 45 (28.1) 9 (37.5)
III 5 (3.1) 1 (4.2)
Not available 28 (17.5) 0 (0)
Number of tumor 0.6269
Single 137 (85.6) 22 (91.7)
Multiple 23 (14.4) 2 (8.3)
Bcl-2 expression 0.0006
= or <10 % 17 (10.9) 11 (39.3)
>10 % 139 (89.1) 17 (60.7)
Ki 67 0.0167
= or <50 % 136 (85.0) 15 (62.5)
>50 % 24 (15.0) 9 (37.5)
Table 1 The clinic-pathologic characteristics of luminal B
HER2-negative breast cancer (Continued)
Adjuvant therapy
Chemotherapy
Yes 133 (83.1) 22 (91.7) 0.1321
Anthracycline/taxane based 72 (45.0) 17 (70.8)
CMF or CNF based 50 (36.9) 5 (20.7)
No 27 (16.9) 2 (8.3)
Hormonal therapy
Yes 148 (92.5) 22 (91.7) 0.0579
SERM 100 (62.5) 9 (37.5)
AI 49 (30.6) 13 (54.2)
No 11 (6.9) 2 (8.3)
Radiation therapy
Yes 110 (68.7) 17 (70.8) 0.9752
No 50 (31.2) 7 (29.2)
TNM tumor size/node/metastasis, AJCC American Joint Committee on Cancer,
BCS breast conserving surgery, SLNB sentinel lymph node biopsy, ALND axillary
lymph node dissection, SERM selective estrogen receptor modulator, AI
aromatase inhibitor, CMF cyclophosphamide/methotrexate/5-fluorouracil,
CNF cyclophosphamide/vinorelbine/5-fluorouracil
Table 2 The analysis of recurrence pattern of luminal B
HER2-negative breast cancer
Recurrence site ER and PR positive
N = 160 (%)
ER or PR negative
N = 24 (%)
p value
Breast 0.7407
No 153 (95.6) 22 (91.6)
Yes 7 (4.4) 2 (8.4)
Bone 0.0297
No 147 (91.9) 18 (75.0)
Yes 13 (8.1) 6 (25.0)
Lung 0.0873
No 152 (95.0) 20 (83.3)
Yes 8 (5.0) 4 (16.7)
Liver 0.0093
No 153 (95.6) 19 (79.2)
Yes 7 (4.4) 5 (20.8)
Brain 0.8510
No 158 (98.7) 23 (95.8)
Yes 2 (1.3) 1 (4.2)
Lymph node 0.2483
Yes 153 (95.6) 21 (87.5)
No 7 (4.4) 3 (12.5)
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better in the ER- and PR-positive group than those in
the ER- or PR-negative group, and there were statisti-
cally significant differences between the two groups
(p = 0.0338, p = 0.0119, respectively) (Fig. 1a, b).
DFS and OS according to negative, low expression, or
positive PR status
We were also interested in whether PR expression level
was associated with prognosis. Thus, we divided the PR-
positive group into low and high PR expression groups
and performed a survival analysis according to PR
expression level. The results showed that low PR expres-
sion group resulted in better DFS (p = 0.0005) and OS
(p < 0.0001) than those of the negative PR expression
group but was worse than that of the high PR expression
group (Fig. 1c, d).
DFS and OS according to Bcl-2 expression status
As we mentioned above, negative ER or PR expression
group showed shorter DFS and OS than positive ER and
PR expression group. In our multivariate analysis, Bcl-2
expression also was a prognostic factor related to ER or
PR expression status. When we analyzed DFS and OS
according to the expression status of Bcl-2, lower Bcl-2
expression has relation with better DFS (p = 0.0007) and
OS (p < 0.0001) (Fig. 2).
Discussion
The ER and PR are expressed in approximately 60~70 %
of breast carcinomas, suggesting that steroid hormones
influence tumor progression [13]. Systematic investiga-
tions into the gene expression patterns in human breast
tumors have provided the basis for improved molecular
taxonomy of breast cancers [21]. Among the four alleged
molecular subtypes of breast cancer, the luminal subtype
expresses ER and/or PR, which is a prognostic factor and
predictive marker for anti-estrogen hormonal therapies,
such as SERM or aromatase inhibitors. However, the
luminal subtype of breast cancer is very heterogeneous,
and its certain subsets have been showing very aggressive
characteristics in clinical setting. Sometimes, their progno-
sis is similar to or worse than that of HER-2-enriched or
triple-negative breast cancers [22]. Bardou et al. had
worked with breast cancer databases to investigate
whether PR status provides additional value to ER status
in patients with primary breast cancer. The results
indicated that PR status is an independent predictive fac-
tor for a benefit from adjuvant anti-estrogen therapy [23].
Our investigators wanted to know the clinical implica-
tions of the negativity of ER or PR in luminal HER2-
negative breast cancer from this study. Our results
showed that ER or PR negativity is poor prognostic
factors, and disease-free survival and overall survival in
the ER- or PR-negative group were shorter than that in
the ER- and PR-positive group. We also wanted to know
the specific role of each hormonal receptor through the
comparison between the ER-negative and PR-negative
groups. As a result, the ER-negative group tended to
have shorter survival than the PR-negative group. Few
studies were conducted on ER-negative and PR-positive
breast cancer because of the low incidence of cases.
These studies showed that ER-negative and PR-positive
breast cancer is associated with older age, higher prolif-
eration, and a worse prognosis [22, 24]. ER-positive and
PR-negative tumors differ from ER-negative and PR-po-
sitive tumors, as shown by our results. When we ana-
lyzed the prognostic value according to the level of PR
expression, the low PR expression group showed an
intermediate prognosis better than the negative PR and
worse than the high PR expression group. Nishimukai
et al. reported that low PR expression is associated with
prognosis of ER-positive and HER2-negative breast
cancer [25], which agrees with our study.
Furthermore, the Arimidex, Tamoxifen, Alone or in
Combination (ATAC) trial showed that patients with
ER-positive and PR-negative tumors have a higher recur-
rence rate than those with ER-positive and PR-positive
tumors. In a subgroup analysis of ER-positive and PR-
negative tumors, the recurrence rate was much higher in
the group that received tamoxifen than that in the group
that received anastrozole [26, 27]. Growing evidence
supports that ER-positive and PR-negative breast cancers
are less responsive to SERM than that of ER-positive
and PR-positive tumors. Because increased crosstalk be-
tween ER and growth factor signaling pathways leads to
downregulated PR transcription, blocking the ER com-
pletely with aromatase inhibitor could be more effective
in patients with ER-positive and PR-negative breast can-
cer [28]. In our study, we have specified a luminal B
HER2-negative breast cancer subgroup to determine
whether ER or PR negativity provides additional prog-
nostic value in patients with high risk HER2-negative
Table 3 Multivariate analysis of factors associated with ER or PR negativity
Variable Coefficient Std. error Odds ratio 95 % CI p value
Age (median 45) −0.64939 0.50740 0.5224 0.1932 to 1.4121 0.2006
Bcl-2 (cutoff 10 %) 1.54314 0.47871 4.6793 1.8310 to 11.9580 0.0012
Ki 67 (cutoff 50 %) −0.70809 0.49583 0.4926 0.1864 to 1.3018 0.1533
CI confidence interval
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endocrine-responsive breast cancer. As a result, the ER-
or PR-negative group showed a higher recurrence rate
and decreased OS compared to the ER- and PR-positive
group. However, we found no difference when we com-
pared anastrozole to tamoxifen in our study because of
the small number of patients.
Several years ago, we had reported the results of study
that Bcl-2 may be a potent prognostic factor in patients
with luminal subtype of breast cancer [17]. Sivestrini et
al. had reported that expression of Bcl-2, an anti-
apoptotic protein, is associated with low-grade, slowly
proliferating, ER-positive breast tumors [29]. There are
several previous studies had shown that increased ex-
pression of Bcl-2 was associated with improved survival
in breast cancer and probability of prognostic role in
endocrine-responsive breast cancer [30, 31]. In our
current study, we also could see the common results
that lower Bcl-2 expression is related with shorter
survival and ER or PR negativity, suggesting that Bcl-2
may be a candidate prognostic factor in patients with
endocrine-responsive breast cancer. There is a study that
when patients were classified into four groups based on
Fig. 1 a Overall survivals of ER- or PR-negative group and ER- and PR-positive group in the luminal B HER-2 negative breast cancer (p = 0.0119). b
Disease-free survivals of ER- or PR-negative group and ER- and PR-positive group in the luminal B HER-2-negative breast cancer (p = 0.0338). c
Overall survivals of PR-positive, PR low, and PR-negative group in the luminal B HER-2-negative breast cancer (p < 0.0001). d Disease-free survivals
of PR-positive, PR low, and PR-negative group in the luminal B HER-2-negative breast cancer (p = 0.0005) (Additional file 1)
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HR and HER2 status, more than 10 % of Bcl-2 expres-
sion in the HR-positive HER2-negative group resulted in
a poorer prognosis, which agrees with our results [32].
We authors cautiously suggest that Bcl-2 expression
might have a prognostic role in luminal B HER2-
negative breast cancer from our current study.
Through the recent studies for gene expression profile
in breast cancer, we had an insight for the role of prolif-
erative signatures in breast cancer in terms of prognosis
and prediction of response to anti-cancer therapy [33].
Ki-67 expression levels varies throughout the different
cell cycle phases, which are low in the G1 and S phases
and reaches its peak level in mitosis [34]. The panel of
the St Gallen International Expert Consensus on the
primary therapy of early breast cancer recommends the
use of proliferation markers such as Ki-67 index when
physicians decide the appropriate systemic treatment in
addition to traditional parameters [35]. However, there
are some arguments between investigators to determine
the appropriate cutoff values of Ki-67 in terms of prog-
nosis of breast cancer or finding out the most potent
subgroup who may get more advantages from anti-
cancer therapy.
Although the role of Ki-67 as a prognostic factor is
controversial in breast cancer, many studies have shown
a relationship between Ki-67 and HR [25, 36]. When we
divided luminal B HER2-negative breast cancer patients
into two subgroups according to a Ki-67 level with
cutoff 50 %, the subgroup with higher Ki-67 (>50 %) was
related with the negative ER or PR group. Nishimukai
et al. reported that high Ki-67 expression and low PR
expression is associated with the prognosis of patients
with ER-positive HER2-negative cancers [25], which
agrees with our results.
Conclusions
ER or PR negativities in patients with luminal B HER2-
negative breast cancer were strongly associated with a
poor prognosis. We observed that ER or PR negativities
are more frequent in patients with luminal B HER2-
negative breast cancer who were older than 45 years old,
had lower Bcl-2 expression, and a higher Ki 67 index.
However, additional studies with large number of patients
who are classified to luminal B HER2-negative breast
cancer subgroup might reveal the role of ER or PR
negativities in breast cancer.
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